Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES StudyKonrad Reinhart, Martin Kaul, Jean‐Louis Vincent et al.|Critical Care Medicine|2001Cited by 261
CD14 receptor occupancy in severe sepsis: Results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14)*Konrad Reinhart, John P. Pribble, Terence Turner et al.|Critical Care Medicine|2004Cited by 80